The present invention relates to the technical field of myopia prevention and control, and in particular to a myopia prevention and control lens and glasses for preventing and controlling myopia. The myopia prevention and control lens comprises: a lens substrate and, provided on the lens substrate, a central optical area and a control area surrounding the periphery of the central optical area; the control area is provided with a plurality of optical microstructure units, and the optical microstructure units are arranged in a non-periodic manner in the control area; the optical microstructure units are used for changing the incident angle of light.
A method for treating a subject suffering from a graft versus host disease (GvHD) or with the risk of GvHD, comprising: selecting a CD90+hAEC cell population with a stronger immunoregulation capability as a primary therapeutic cell. Research on related action mechanisms finds that the stem cell pluripotent markers SSEA4, OCT4 and NANOG of CD90+hAECs are significantly higher than general hAECs, and have better immunomodulatory functions, and therefore, the CD90+hAECs cells are used as therapeutic means to obtain better clinical results.
The present disclosure provides the utilization of an RPN11 marker in detecting myeloma and assessing disease risk, prognostic analysis, and therapeutic drug development. This includes a detection reagent and a kit for detecting smoldering multiple myeloma (SMM) and multiple myeloma (MM) and assessing disease risk. Additionally, it involves molecular typing of MM patients' cassette, prognostic analysis of the MM patients, and predicting the response of the MM patients to a bortezomib treatment. It entails the use of an RPN11 inhibitor in preparation of a pharmaceutical composition for treating MM characterized by drug-resistant t(4;14) translocation and a high RPN11 expression level. Notably, the combined use of the RPN11 with histone methyltransferase (HMT) enhances detection sensitivity and accuracy, preventing a mismatch between the patients' genotype and the prediction of disease development, and can effectively predict the overall survival and prognosis of MM patients with t(4;14) translocation.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
4.
MYOPIA PREVENTION AND CONTROL SPECTACLE LENS HAVING FRACTAL MICROSTRUCTURE
The present invention relates to the technical field of design and processing of optical lenses, and provides a myopia prevention and control spectacle lens having a fractal microstructure. The spectacle lens comprises a lens base; an optical area and a control area are provided on the lens base; the optical area comprises a central optical area, and the central optical area is an area having the center position of the spectacle lens as a center and a radius of R1; the control area surrounds the central optical area, and the control area is provided with a microstructure constructed by a fractal curve or fractal pattern on the plane of the lens base, or a microstructure constructed by a fractal curve or fractal pattern between layers of the lens base. According to the present invention, the degree of optical disturbance is increased by increasing the complexity of the peripheral microstructure as much as possible, thereby interfering with the process of myopia progression.
Disclosed is use of an RPN11 marker in the detection of myeloma and disease risk thereof, prognosis analysis and a treatment medicament, comprising: a detection reagent and a kit for detecting smoldering myeloma, multiple myeloma and disease risk thereof, molecular typing of patients with multiple myeloma, prognosis analysis of the patients with multiple myeloma, and predicting the treatment reactivity to bortezomib of multiple myeloma patients, and use of an RPN11 inhibitor in the preparation of a pharmaceutical composition for treating drug-resistant t(4; 14) translocation and RPN11 high-expression multiple myeloma. In particular, combining the RPN11 and histone methyltransferase MMSET provides more sensitive and accurate detection performance, avoids situations of patient genotype not matching disease development predictions, while total survival and prognosis conditions of MM patients with t(4;14) translocation can be effectively predicted. Furthermore, the pharmaceutical composition has a synergistic effect, thereby effectively promoting the apoptosis of the multiple myeloma cells with t(4;14) translocation.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
Provided is a reagent composition for immunophenotyping and MRD monitoring of B lymphoblastic leukemia/lymphoma (B-ALL/LBL). The reagent composition includes a 20-antibody combination. In the present disclosure, the antibody combination, the fluorescent labeling combination for the corresponding antibody, and the result interpretation methods are optimized. It only needs to use 20 kinds of antibodies in a single tube of cells for one sample loading, allowing for comprehensively and efficiently performing subtype typing on B lymphoblastic leukemia/lymphoma. In addition, it enables to predict part of recurrent genetically abnormal B-ALL/LBL and has high sensitivity and specificity for the diagnosis of the subtype of BCR/ABL1 gene. Meanwhile, it enables to determine the leukemia-related immunophenotype (LAIP) for minimal residual disease (MRD) monitoring after treatment by using the combination and used for MRD monitoring and CAR-T post-treatment monitoring.
The present disclosure relates to the field of antibody medicine and in particular to an antibody composition for immunotyping of myeloid neoplasms and use thereof, the antibody composition comprising panels of 22-24 antibodies. In the disclosure, combinations of antibodies and corresponding fluorescent labels as well as the method for interpreting the results are optimized, which, with only one tube of 22 or 24 antibodies and one tube of cells at a time, allows for comprehensive and efficient subtyping of acute myeloid leukaemia (AML) and chronic myeloid neoplasms, prediction of CML and part of AML with recurrent genetical abnormalities, and thus a high sensitivity for the diagnosis of myelodysplasia (MDS). It is also possible to identify leukaemia-associated immunophenotypes (LAIP) in this composition that can be used for post-treatment minimal residual disease (MRD) monitoring.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
8.
Urine-Derived Mesenchymal Stem Cell Mitochondria as Well as Transplantation Method and Use Thereof
A urine-derived mesenchymal stem cell mitochondria as well as a transplantation method and use thereof. The urine-derived mesenchymal stem cell mitochondrion is extracted from urine to be used for improving the quality of oocytes. The transplantation method comprises: jointly injecting sperms and the urine-derived mesenchymal stem cell mitochondria into mature oocytes for blastaea culture during the intracytoplasmic sperm microinjection. The present disclosure has the beneficial effects: during the traditional ICSI in combination with the transplantation of the urine-derived mesenchymal stem cell mitochondria, the fertilization rate of human in-vitro fertilization and the quality of embryos are significantly improved; the urine-derived mesenchymal stem cell mitochondria of the present disclosure can be used for in-vitro fertilization of low-prognosis patients with infertility with a good treatment effect; the problem of an autologous mitochondrion source in the prior art is solved without involving the introduction of a third-party genetic material and ethical issues.
A method for treating a subject suffering from a graft versus host disease (GvHD) or with the risk of GvHD, comprising: selecting a CD90+hAEC cell population with a stronger immunoregulation capability as a primary therapeutic cell. Research on related action mechanisms finds that the stem cell pluripotent markers SSEA4, OCT4 and NANOG of CD90+hAECs are significantly higher than general hAECs, and have better immunomodulatory functions, and therefore, the CD90+hAECs cells are used as therapeutic means to obtain better clinical results.
Provided are a nucleic acid of an isolated encoding SCAP mutant, an isolated SCAP polypeptide, a method and a system for screening for biological samples that easily contract premature myocardial infarction, and a kit used to screen for biological samples that easily contract premature myocardial infarction. The nucleic acid of the isolated encoding SCAP mutant has c.3035C>T mutation as compared with SEQ ID NO:1.
C12N 15/12 - Gènes codant pour des protéines animales
C07K 14/46 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
11.
HEPATITIS C VIRUS B CELL EPITOPE PEPTIDE PUHI26 AND APPLICATIONS THEREOF
Provided is a hepatitis C virus B cell epitope peptide PUHI26, where the amino acid sequence thereof is THKFNSSGCPERMASCRPID. Also provided is a protective antibody capable of neutralizing hepatitis C virus 1a, 1b, 3a, 4a, 5, and 6 genotype/subtype HCVpp.
A HBV mutation strain is provided, wherein rtE218G mutation occurs at the polymerase region of the mutation strain. The use of the HBV strain in screening anti-HBV drugs and related detection reagents used to detect rtE218G mutation are also provided.
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12N 15/01 - Préparation de mutants sans introduction de matériel génétique étrangerProcédés de criblage à cet effet
An anti-HCV vaccine, which is prepared through recombination of NS genes in series, including NS3/NS4 and NS4/NS5, with adenovirus vector. The preparation methods and uses of the anti-HCV vaccine.
C07K 14/18 - Togaviridae, p. ex. flavivirus, virus de la peste, virus de la fièvre jaune, virus de l'hépatite C, virus de l'encéphalite japonaise
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 31/14 - Antiviraux pour le traitement des virus ARN
14.
UTILIZING LIVER CELL LINE QSG-7701 TO BE INFECTED WITH HEPATITIS B VIRUS
Utilizing liver cell line QSG-7701 to be infected with hepatitis B virus, which comprising the step of directly infecting the cultured QSG-7701 with the purified hepatitis B virus particles. Treatment with DMSO or adding PEG can assist infection. The origin of the liver cell line QSG-7701 can be easily obtained. The cell line can be infected with HBV naturally without pre-induction of differentiation, which is closer to the situation of liver cell being infected with HBV infecting in vivo and is more suitable for the characteristics of the race of Chinese. It is suitable for the study of the life cycle of HBV, especially the study of the process of infection and the study of medicines specific for the targets related with the process of infection.
brevets
